A Pennsylvania biotechnology company is raising $1.5 million to advance its human antibody cloning technology that it believes has broad applications for the treatment of unmet medical needs such as Alzheimer’s disease, cancer, infectious diseases and bioterror attacks.
In its latest financing round, begun Jan. 4, Immunome has raised $145,000.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
Dr. Scott K. Dessain, the founder and chief science officer of Immunome, is an associate professor with the Lankenau Institute for Medical Research in Wynnewood, Pennsylvania.
The CEO of Immunome, Timothy Pelura, is a serial entrepreneur in life sciences with more than 35 years of experience in the pharmaceutical, biotechnology and medical device sectors, according to the company’s website. He has served as CEO of Promedior, a biotech company that developed therapeutics for the treatment of fibrotic disorders and diseases. He also worked at Kereos, Provasis Therapeutics, Neuron Therapeutics and Alliance Pharmaceutical Corp., according to the company’s website.
Among its investors are BioAdvance, the biotechnology greenhouse of Southeastern Pennsylvania and I Wistar Morris III, an investment banker, along with private investors.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.